A population-based evaluation of the seventh edition of the TNM system for lung cancer

European Respiratory Journal

Volumn 36, Issue 2, 2010, Pages 401-407

  Strand, T E ^a   Rostad, H ^a   Wentzel Larsen, T ^b   Von Plessen, C ^c,d  

^a Cancer Registry of Norway ^*  (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d HILLERØD HOSPITAL   (Denmark)

Author keywords

Evaluation; Lung cancer; Population based; Seventh edition; TNM

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; EVALUATION; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NORWAY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; PULMONARY MEDICINE; REGISTRIES; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE;

EID: 77955629229     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00171809     Document Type: Article

References (21)

1. Lung and pleural tumours. In: Goldstraw P, ed. International Association for the Study of Lung Cancer. Staging Manual in Thoracic Oncology. Editorial Rx Press, Florida, 2009; p. 164.
2. Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol 2006; 1: 281-286.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
4. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 694-705.
5. Fukui T, Mori S, Hatooka S, et al. Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. J Thorac Cardiovasc Surg 2008; 136: 1343-1348.
6. Kameyama K, Takahashi M, Ohata K, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J Thorac Cardiovasc Surg 2009; 137: 1180-1184.
7. Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol 2008; 3: 216-227.
8. Cancer Registry of Norway. Cancer in Norway 2006. Cancer incidence, mortality, survival and prevalence in Norway. Oslo, Cancer Registry of Norway, 2007. www.kreftregisteret.no/Global/Publikasjoner%20og%20rapporter/CiN2006-web. pdf
9. Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45: 1218-1231.
10. Strand TE, Rostad H, Møller B, et al. Survival after resection for primary lung cancer: a population-based material of 3,211 resected patients. Thorax 2006; 61: 710-715.
11. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
12. Goldstraw P. The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 2009; 4: 671-673.
13. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005; 50: 227-234.
14. Naruke T, Tsuchiya R, Kondo H, et al. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001; 71: 1759-1764.
15. Inoue K, Sato M, Fujimura S, et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 1998; 116: 407-411.
16. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101: 878-887.
17. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27: 5068-5074.
18. Birim O, Kappetein AP, van Klaveren RJ, et al. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006; 32: 12-23.
19. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
20. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
21. Goldstraw P, Crowley J, Chansky K, et al. The IASLC: Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714. (Pubitemid 47357522)